[

bharat biotech

]
Additional secretary in the Union ministry of health and family welfare Manohar Agnani said in the last 24 hours another death following vaccination has been recorded in Gurugram(PTI)

None of the deaths preceded by inoculation linked to Covid-19 vaccination

By hindustantimes.com | Edited by Ayshee Bhaduri, Hindustan Times, New Delhi
PUBLISHED ON JAN 23, 2021 11:00 PM IST
Additional secretary of the union health ministry Manohar Agnani, said on Saturday that a total of 11 hospitalisations have been recorded following immunizations, taking the percentage of hospitalization against vaccination to 0.0007%.
Close
Adverse reactions can be caused by allergies or underlying medical conditions and are not necessarily causally linked to vaccines.(Bloomberg Photo )
Adverse reactions can be caused by allergies or underlying medical conditions and are not necessarily causally linked to vaccines.(Bloomberg Photo )

Covaxin recipients under stricter watch, says Centre

By Rhythma Kaul, New Delhi
UPDATED ON JAN 20, 2021 03:54 AM IST
Union health secretary Rajesh Bhushan said Bharat Biotech’s Covaxin vaccine recipients are being actively followed for any adverse reactions. Officials also drew a distinction between Covishield, which finished late-stage trials abroad, and Covaxin, which is currently in phase 3 trials.
Close
A healthcare worker fills a syringe with a dose of Bharat Biotech's COVID-19 vaccine called COVAXIN, during the coronavirus disease (COVID-19) vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, January 16, 2021. REUTERS/Adnan Abidi(REUTERS)
A healthcare worker fills a syringe with a dose of Bharat Biotech's COVID-19 vaccine called COVAXIN, during the coronavirus disease (COVID-19) vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, January 16, 2021. REUTERS/Adnan Abidi(REUTERS)

Centre issues Letter of Comfort to Bharat Biotech for 45 lakh doses of Covaxin

PTI, Hyderabad
PUBLISHED ON JAN 19, 2021 12:21 PM IST
Out of the 45 lakh doses, the city-based vaccine maker will be supplying over eight lakh to some of the friendly countries such as Mauritius, Philippines and Myanmar, free of cost as good will gesture.
Close
AIIMS director Randeep Guleria receives a dose of the Bharat Biotech's Covaxin on Saturday.(Bloomberg)
AIIMS director Randeep Guleria receives a dose of the Bharat Biotech's Covaxin on Saturday.(Bloomberg)

'Advisable to not take vaccine if...': Bharat Biotech issues Covaxin fact sheet

By hindustantimes.com | Edited by Amit Chaturvedi
UPDATED ON JAN 19, 2021 09:37 AM IST
According to Bharat Biotech, it is advisable not to take the vaccine if a person has allergies, fever or bleeding disorder or is on a blood thinner.
Close
Manish Kumar said it wasn’t a coincidence that he was a part of the first batch of frontline staffers at the premier AIIMS to be vaccinated, all of whom received a jab of Bharat Biotech’s Covaxin.(REUTERS)
Manish Kumar said it wasn’t a coincidence that he was a part of the first batch of frontline staffers at the premier AIIMS to be vaccinated, all of whom received a jab of Bharat Biotech’s Covaxin.(REUTERS)

Manish Kumar first to take shot in Delhi

By shiv sunny, New Delhi
PUBLISHED ON JAN 17, 2021 01:20 AM IST
Manish Kumar on Saturday emerged as the face of a months-long global effort against time to develop an inoculation against the infection that has killed over two million people. He said he always believed in the efficacy and safety of the vaccine.
Close
No comments were made on the reports that many doctors expressed apprehension about taking the Covaxin shot.(Bloomberg Photo )
No comments were made on the reports that many doctors expressed apprehension about taking the Covaxin shot.(Bloomberg Photo )

Concerns over Covaxin as some cite ‘lack of data’

By HT Correspondent, New Delhi
PUBLISHED ON JAN 17, 2021 01:14 AM IST
The controversy escalated during the day as reports said those receiving Bharat Biotech’s Covaxin were asked to sign consent forms before being inoculated because the jab had been allowed by the government in “clinical trial mode”.
Close
The drive began simultaneously across dedicated vaccination centres set up across the country, where doses of Covishield and indigenously developed Covaxin were administered to people.
The drive began simultaneously across dedicated vaccination centres set up across the country, where doses of Covishield and indigenously developed Covaxin were administered to people.

Shielded and vaccinated: India begins mammoth immunisation drive

By HT Correspondent, New Delhi
PUBLISHED ON JAN 17, 2021 01:04 AM IST
According to data compiled from states by HT, 200,297 people were vaccinated. The number was shy of the 300,000 that was being estimated but still far higher than what was recorded by any country on its first day.
Close
Karnataka Chief Minister B S Yediyurappa addresses the media at Vidhan Soudha in Bengaluru.(PTI)
Karnataka Chief Minister B S Yediyurappa addresses the media at Vidhan Soudha in Bengaluru.(PTI)

News updates from Hindustan Times: 7 to be inducted into Karnataka cabinet today

By hindustantimes.com
UPDATED ON JAN 13, 2021 12:54 PM IST
Here are today’s top news, analysis and opinion. Know all about the latest news and other news updates from Hindustan Times.
Close
The government has trained 2,360 master trainers, who in turn have trained 61,000 programme managers, 200,000 vaccinators and 370,000 other vaccination team members so far. (Representative Image)
The government has trained 2,360 master trainers, who in turn have trained 61,000 programme managers, 200,000 vaccinators and 370,000 other vaccination team members so far. (Representative Image)

People won’t be given vaccine choice: Govt

UPDATED ON JAN 13, 2021 01:38 AM IST
Both vaccine candidates have won approval from the Drugs Controller General of India (DGCI) although Covaxin is still in Phase 3 trials.
Close
Inside views of the production and processing unit of Serum Institute of India (SII) in Pune on Tuesday. (ANI Photo )
Inside views of the production and processing unit of Serum Institute of India (SII) in Pune on Tuesday. (ANI Photo )

Explained: Who gets Covid-19 vaccine jabs in first two phases, what's the price

By hindustantimes.com | Written by Kanishka Sarkar, Hindustan Times, New Delhi
PUBLISHED ON JAN 12, 2021 08:10 PM IST
Union health secretary Rajesh Bhushan on Tuesday said the Covid-19 vaccine may cost in the range of 200 to 295 in India.
Close
Addressing a press briefing, Union Health Secretary Rajesh Bhushan said vaccine effectiveness will be seen only after 14 days.(HT Photo)
Addressing a press briefing, Union Health Secretary Rajesh Bhushan said vaccine effectiveness will be seen only after 14 days.(HT Photo)

Gap of 28 days between two Covid-19 vaccine doses: Govt

PTI
UPDATED ON JAN 12, 2021 11:11 PM IST
India had recently granted emergency use authorisation to two vaccines, Oxford's Covishield being manufactured by Serum Institute of India and Bharat Biotech's Covaxin. Both vaccines, the statement from the Health Ministry said, have established safety and immunogenicity.
Close
China on Tuesday locked down a city of 4.9 million residents near Beijing as authorities continued to battle a surge in Covid-19 infections across the country.(via REUTERS)
China on Tuesday locked down a city of 4.9 million residents near Beijing as authorities continued to battle a surge in Covid-19 infections across the country.(via REUTERS)

News updates from HT: China puts 20 mn people under lockdown as Covid-19 surges

By hindustantimes.com
UPDATED ON JAN 12, 2021 05:17 PM IST
Here are today’s top news, analysis, and opinion at 5pm. Know all about the latest news and other news updates from Hindustan Times.
Close
Representational image.(AFP)
Representational image.(AFP)

Serum Institute, Bharat Biotech pledge smooth Covid-19 vaccine roll-out

By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON JAN 05, 2021 05:03 PM IST
Both the vaccine makers on Tuesday communicated their combined intent to develop, manufacture and supply Covid-19 vaccines
Close
Manish Tewari accused the government of politically misusing the Covid-19 pandemic.(Sonu Mehta/HT File Photo)
Manish Tewari accused the government of politically misusing the Covid-19 pandemic.(Sonu Mehta/HT File Photo)

Who will opt for a vaccine with question marks on its reliability: Manish Tewari

By hindustantimes.com | Edited by Kanishka Sarkar | Hindustan Times, New Delhi
UPDATED ON JAN 05, 2021 01:24 PM IST
Drug Control General of India (DCGI) on Sunday approved the Oxford University-AstraZeneca Covid-19 vaccine, Covishield, and Bharat Biotech’s Covaxin for restricted emergency use.
Close
A volunteer being vaccinated by a medic during the Bharat Biotech's 'Covaxin' human trial in Jaipur.(PTI)
A volunteer being vaccinated by a medic during the Bharat Biotech's 'Covaxin' human trial in Jaipur.(PTI)

‘Give me one week’s time’: Bharat Biotech chief on questions about Covaxin efficacy

By hindustantimes.com | Edited by Shivani Kumar | Hindustan Times, New Delhi
UPDATED ON JAN 04, 2021 08:56 PM IST
The government has cleared Bharat Biotech International Limited’s locally developed vaccine for “restricted use in emergency situation” triggering a debate among experts over the approval despite the shorter duration of human trials and relatively less data
Close
ABCVAC described its planned deal with Bharat Biotech as a way to ensure Brazilians using the private health system, typically the wealthy, would have access to a vaccine(REUTERS)
ABCVAC described its planned deal with Bharat Biotech as a way to ensure Brazilians using the private health system, typically the wealthy, would have access to a vaccine(REUTERS)

Brazil’s private clinics seek deal for Bharat Biotech’s Covaxin

By Agence France-Presse | Posted by Ayshee Bhaduri | Rio de Janeiro
PUBLISHED ON JAN 04, 2021 12:52 PM IST
The Brazilian Association of Vaccine Clinics confirmed on its website it had signed a memorandum of understanding with the Indian firm to purchase its Covaxin vaccine, which is currently in the final stage of clinical trials.
Close
Doses of the Covid-19 vaccine developed by Oxford University and UK-based drugmaker AstraZeneca are checked as they arrive at the Princess Royal Hospital in Haywards Heath, England.(AP File photo)
Doses of the Covid-19 vaccine developed by Oxford University and UK-based drugmaker AstraZeneca are checked as they arrive at the Princess Royal Hospital in Haywards Heath, England.(AP File photo)

Oxford, Bharat Biotech vaccines cleared for use

By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON JAN 04, 2021 01:31 AM IST
The Subject Expert Committee consists of domain experts from the fields of pulmonology, immunology, microbiology, pharmacology, paediatrics, internal medicine and so on .
Close
The Drugs Controller General of India (DCGI) on Sunday gave licensing permission to Bharat Biotech to manufacture Covaxin(ANI)
The Drugs Controller General of India (DCGI) on Sunday gave licensing permission to Bharat Biotech to manufacture Covaxin(ANI)

News updates from Hindustan Times: DGCI gives permission to Bharat Biotech for manufacturing Covaxin and all the latest news

By hindustantimes.com | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 09:01 PM IST
Here are today’s top news, analysis, and opinion at 9pm. Know all about the latest news and other news updates from Hindustan Times.
Close
The DCGI granted the approval on the basis of recommendations of a Covid-19 Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).(PTI)
The DCGI granted the approval on the basis of recommendations of a Covid-19 Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).(PTI)

DCGI gives licensing permission to Bharat Biotech to manufacture Covaxin

By hindustantimes.com| Edited by Susmita Pakrasi | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 08:58 PM IST
The DCGI gave final approval to two Covid-19 vaccines, paving the way for a huge inoculation program to stem the pandemic in the second worst-hit country.
Close
JP Nadda hailed the contribution of scientists and innovators in developing a vaccine within a year of the Covid-19 pandemic striking India(PTI Photo)
JP Nadda hailed the contribution of scientists and innovators in developing a vaccine within a year of the Covid-19 pandemic striking India(PTI Photo)

‘More they oppose, more they are exposed’: Nadda hits out at Congress over Covid-19 vaccine ‘doubts’

By hindustantimes.com | Edited by Kanishka Sarkar | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 05:51 PM IST
Nadda accused the Congress of spreading lies and politicising the vaccine issue and alleged that the Congress and the Opposition is not proud of anything Indian.
Close
A medic fills a syringe with Covaxin, a government-backed experimental Covid-19 vaccine, before administering it to a health worker during its trials.(Reuters File Photo)
A medic fills a syringe with Covaxin, a government-backed experimental Covid-19 vaccine, before administering it to a health worker during its trials.(Reuters File Photo)

Approval for Covaxin a giant leap for novel product development in India: Bharat Biotech

By Press Trust of India | Posted by Kanishka Sarkar | New Delhi
PUBLISHED ON JAN 03, 2021 02:58 PM IST
The phase-III human clinical trials of Covaxin began mid-November. Bharat Biotech aims to recruit 26,000 volunteers across the country for the phase-III trials.
Close
Vials and a medical syringe are seen in front of a displayed AstraZeneca logo in this illustration taken October 31, 2020.(REUTERS FILE)
Vials and a medical syringe are seen in front of a displayed AstraZeneca logo in this illustration taken October 31, 2020.(REUTERS FILE)

‘Ready to roll-out’: Adar Poonawala after Covishield, Covaxin win limited use nod

By Rhythma Kaul | New Delhi, Hindustan Times
UPDATED ON JAN 03, 2021 12:50 PM IST
The drugs controller announced that he accepted recommendations made by the subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Friday and Saturday to grant restricted emergency approval to both the vaccines
Close
A health worker takes part in a dry run or a mock drill for Covid-19 vaccine delivery at a model vaccination centre at Ansari Road in New Delhi.(Sanchit Khanna/HT Photo)
A health worker takes part in a dry run or a mock drill for Covid-19 vaccine delivery at a model vaccination centre at Ansari Road in New Delhi.(Sanchit Khanna/HT Photo)

Drug regulator gives final approval for Covid-19 vaccines of SII, Bharat Biotech

By HT Correspondent | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 01:55 PM IST
Covaxin is the indigenous vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Close
‘No vaccine belongs to any political party’ says Omar Abdullah after Akhilesh Yadav rejects Covid-19 vaccine.(PTI)
‘No vaccine belongs to any political party’ says Omar Abdullah after Akhilesh Yadav rejects Covid-19 vaccine.(PTI)

News updates from Hindustan Times: Omar Abdullah says vaccines belong to no political party after Akhilesh Yadav’s ‘BJP vaccine’ comment and all the latest news

By hindustantimes.com | Hindustan Times, New Delhi
UPDATED ON JAN 02, 2021 09:07 PM IST
Here are today’s top news, analysis, and opinion. Know all about the latest news and other news updates from Hindustan Times.
Close
A volunteer being vaccinated by a medic during the Bharat Biotech's 'Covaxin' human trial in Jaipur.(PTI)
A volunteer being vaccinated by a medic during the Bharat Biotech's 'Covaxin' human trial in Jaipur.(PTI)

Covaxin approval: All you need to know about Bharat Biotech Covid-19 vaccine’s efficacy, price

By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON JAN 02, 2021 10:00 PM IST
Bharat Biotech followed a double-bind, randomised, multi-centre phase two clinical trial which included children as well. Its third phase trial is still going on.
Close
A medic administers Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), during the Phase- 3 trials at the People's Medical College in Bhopal.(PTI)
A medic administers Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), during the Phase- 3 trials at the People's Medical College in Bhopal.(PTI)

Expert panel recommends Bharat Biotech’s Covaxin for restricted emergency use

By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON JAN 02, 2021 10:07 PM IST
This will be the first indigenous vaccine against Covid-19, developed by Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology.
Close
Representational photo.(REUTERS File)
Representational photo.(REUTERS File)

Bharat Biotech’s Covid-19 vaccine phase-3 trials cross half-way mark of 13,000 volunteers

By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON DEC 22, 2020 12:57 PM IST
Covaxin, India’s indigenous Covid-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research-National Institute of Virology
Close
Bharat Biotech has developed the whole-virion inactivated SARS-CoV-2 vaccine candidate (BBV152) in collaboration with ICMR.(Reuters File Photo)
Bharat Biotech has developed the whole-virion inactivated SARS-CoV-2 vaccine candidate (BBV152) in collaboration with ICMR.(Reuters File Photo)

Bharat Biotech’s Covaxin safe, says Phase 1 trial data

By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON DEC 17, 2020 05:47 AM IST
The results of Phase 1 results of Covaxin had not been publicly released yet even though the data was first presented to Drugs Controller General of India (DCGI) on October 2 when the company applied for approval to start Phase 3 trials.
Close
The vaccine is being stored between 2-8 degrees Celcius and further efficacy trials are underway.(Reuters file photo. Representative image)
The vaccine is being stored between 2-8 degrees Celcius and further efficacy trials are underway.(Reuters file photo. Representative image)

Covaxin’s phase 1 trial result shows robust immune response, mild adverse events

By hindustantimes.com| Edited by: Harshit Sabarwal | Hindustan Times, New Delhi
UPDATED ON DEC 16, 2020 09:49 PM IST
The results of the first phase of Covaxin- which Bharat Biotech is developing in collaboration with the Indian Council of Medical Research (ICMR) comes a day after the Drugs Controller General of India (DGCI) had said that it was examining the application submitted by the company seeking emergency use authorisation of its vaccine.
Close
SHARE
  • 1
  • 2
  • 3
  • ...
Story Saved